Elzovantinib (TPX-0022; p.o., BID, 13 days) treatment results in an 85% tumor regression and no body weight loss is observed after 21 days treatment in mice[1].
Elzovantinib (p.o., BID, 10 days) demonstrates the ability to inhibit tumor growth at 44% and 67% at the dose of 5 mg/kg, BID and 15 mg/kg, BID, respectively in SCID/Beige mice[1].
Elzovantinib inhibits MET activity in MKN-45 tumors following oral administration in mice[1].
| Animal Model: | Mice bearing LU2503 tumors patient derived xenograft (PDX) NSCLC model[1]. |
| Dosage: | 15 mg/kg. |
| Administration: | PO, BID (twice daily) for 13 days. |
| Result: | Resulted in an 85% tumor regression and no body weight loss was observed after 21 days treatment. |
| Animal Model: | SCID/Beige mice bearing Ba/F3 ETV6-CSF1R tumors with average tumor size of ~180 mm3[1]. |
| Dosage: | 5 and 15 mg/kg. |
| Administration: | PO, BID (twice daily) for 10 days. |
| Result: | Demonstrated the ability to inhibit tumor growth at 44% and 67% at the dose of 5 mg/kg, BID and 15 mg/kg, BID, respectively. |
